Amgen Inc. logo

Amgen Inc. (AMGN)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
432. 49
-1.54
-0.3548%
After Hours
$
439. 00
+6.51 +1.5052%
223.91B Market Cap
19.61 P/E Ratio
0.07% Div Yield
2.56M Volume
18.58 Eps
$ 434.03
Previous Close
Add Transaction
Day Range
431.43 438.82
Year Range
288 447.03
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term

Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Amgen Shares Cross Above 200 DMA

Amgen Shares Cross Above 200 DMA

In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.

Forbes | 1 year ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 1 year ago
Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Amgen Inc. (NASDAQ:AMGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capparelli Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst So we have Paul Burton. He's the Chief Medical Officer of the company; and dabbing for the first time, Adam Elinoff, the new IR at Amgen.

Seekingalpha | 1 year ago
Here's Why Amgen (AMGN) is a Strong Value Stock

Here's Why Amgen (AMGN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.

Zacks | 1 year ago
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.

Zacks | 1 year ago
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly

Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.

Zacks | 1 year ago
Loading...
Load More